Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + docetaxel + doxorubicin
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of bevacizumab, docetaxel, and doxorubicin. Bevacizumab is a monoclonal antibody that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF-A), preventing the growth of blood vessels to cancer cells. Docetaxel is a taxane that disrupts microtubule function, and doxorubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II. This combination leverages multiple mechanisms to target cancer cells and their blood supply.
- Other names
- bevacizumab/docetaxel/doxorubicin
02
Targets
Beyond the preview
Go deeper on bevacizumab + docetaxel + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + docetaxel + doxorubicin.